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INTRODUCTION
MicroAlbuminuria (MA) is defined as urine albumin excretion rate of 
30  to  300  mg/day or  20  –  200  µg/min  in  a  randomly collected 
sample.
MicroAlbuminuria  is  thought  to  be  a  marker  of  widespread 
vascular damage and reflects the systemic transcapillary leakage of 
albumin.  
The significance of  MicroAlbuminuria in  relation to Diabetes 
has been extensively studied and documented in  literature.   The 
structural,  functional  and  biochemical  aspects  contributing  to 
MicroAlbuminuria  is  the  basis  of  numerous  past  and  ongoing 
studies.   The  prevalence,  progression  and  regression  of 
MicroAlbuminuria  in  various  disease  processes  like  diabetes, 
hypertension  and  coronary  artery  disease  was  repeatedly 
investigated  in  several  land  mark  trials  and  have  confirmed  its 
significance.
There  are  a  few  published  studies  from  West  on 
MicroAlbuminuria  in  Cerebrovascular  diseases.    Observations 
made  out  of  these  studies  confirm  the  association  of 
MicroAlbuminuria  in  cerebrovascular  disease   similar  to  those  in 
vascular disorders of Heart and Kidney.  Unfortunately such reports 
are lacking from our country.  
          Hence an attempt has been made to study MicroAlbuminuria 
among  Non–diabetic  cerebrovascular  accident  patients  from  this 
part of the country.  
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                           ABBREVIATIONS
MA –MicroAlbuminuria 
MI –Myocardial Infarction 
DM –Diabetes Mellitus 
HTN–Hypertension 
TIA –Transient Ischemic Attack 
AVM–ArterioVenous Malformation 
ESR –Erythrocytic Sedimentation Rate
CT –Computed Tomogram 
MR –Magnetic Resonance 
GCS –Glasgow Coma Scale  
LVH –Left Ventricular Hypertrophy
UAE–Urine Albumin Excretion
PCR–Protein Creatinine Ratio
ACR–Albumin Creatinine Ratio 
CBF–Cerebral Blood Flow 
CBV–Cerebral Blood Volume 
DWI–Diffussion Weighted Imaging 
PWI–Perfusion Weighted Imaging 
NAA–N Acetyl Aspartate
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AIM OF THE STUDY
1.  To estimate the prevalence of Microalbuminuria in Non–Diabetic 
Acute  Ischemic Stroke.
2.   To assess the prognostic significance of Microalbuminuria in 
these cases with reference to Glasgow coma scale of the patient.
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REVIEW OF LITERATURE
                                         MICROALBUMINURIA
Historical Aspects 
In 1963 Harry Keen was looking to document the earliest sign 
of renal disease in the Bedford survey.  Clinical proteinuria was the 
hallmark  of  nephropathy but  he wanted to measure the smallest 
amount.  At  a British Diabetic Association meeting Harry and his 
colleague Costis Chlouverakis heard the description of the method 
of measuring the amount of insulin by precipitating the amount of 
insulin – insulin – Antibody complex with the second, antiglobulin 
antibody.   Soon they immunized  a  few guinea  pigs  with  human 
albumin and with in a few months had discovered microalbuminuria 
(29).
Surprisingly  the  Ames  company  in  1950s,  introduced  the 
‘Albutest’ for urine protein but it  was immediately withdrawn since 
clinicians complained that it came out with false positive results in 
whom the standard sulphosalicylic test was negative.  In fact the 
Albutest was so sensitive that it was detecting Microalbuminuria .
By 1982 MicroAlbuminuria  was shown to  a marker  of  early 
nephoropathy(30) and later a more general indicator of a bad blood 
vessels.  
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Since then the methodologies for detecting MicroAlbuminuria 
has  grown  by  leaps  and  bounds  with  increasing  sensitivity  and 
specificity.  The role of MicroAlbuminuria from a simple marker of 
early nephoropathy, has now  changed to a harbinger for predicting 
the development and prognosis of vascular diseases of Heart, Brain, 
Kidney as well and as a marker of severity of inflammatory process 
in various settings.
EPIDEMIOLOGY
Urinary  albumin  excretion  measurement  was  undertaken  in 
multitude of varying studies in all  continents and was found to be 
equally varying across different classes, age group, diseased and 
normal individuals.
AGE, GENDER AND ETHNIC VARIATIONS
Advanced age and male  sex were more frequently seen in 
patients with increased levels of albuminuria (31).  MicroAlbuminuria 
in  general  population studied in  Britain was found to vary widely 
between  Ethnic  groups  and  ranged  between  2.2–10.2%(1,2). 
Prevalence as high as 39 and 42% was found in Aborigine men and 
women respectively(3).
MICROALBUMINURIA IN DIABETES
MicroAlbuminuria in Type I Diabetes was found to be prevalent 
in 3.7 – 40% and in Type II Diabetes between 30 – 40% (4,5,6).  The 
duration of  diabetes was significantly longer in  microalbuminurics 
than normoalbuminurics. 
        In the micro – HOPE study, MicroAlbuminuria was detected in 
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32.2%  in  diabetic  participants  and  14.7%  in  non  –  diabetic 
participants.   Age,  waist  to  hip  ratio,  diabetes,  hypertension, 
smoking, vascular disease and LVH were independent determinants 
of MicroAlbuminuria in all participants (5).  Mykkanen et al (7) in a 
study  of  1449  patients  showed  a  higher  prevalence  of 
MicroAlbuminuria in diabetes (27.6%) than in non–diabetes (13.9%).
MICROALBUMINURIA IN HYPERTENSION
MicroAlbuminuria in hypertensives was found to be prevalent in 
3–37.5% patients in various studies(8,41).
MICROALBUMINURIA IN STROKE
Prevalence of MicroAlbuminuria in acute stroke was found to 
be between 30–46%. MicroAlbuminuria in non–diabetic stroke was 
found  to  be  about  46%  compared  to  13.5%  in  controls  studied 
several  months  after  stroke.The  prevalence  of  MicroAlbuminuria 
was 3 fold greater in patients with recent stroke when compared to 
controls with the same profile of cardiovascular risk factors (9,10).
The PREVEND (Prevention of REnal and Vascular ENd Stage 
Disease)  study  (31)  prospectively  studied  the  natural  course  of 
MicroAlbuminuria  in  inhabitants  of  The  city  of  Groningen  (  The 
Netherlands) between the age group of 28 to 75 years and came up 
with the following findings:-
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Table No – 1:PREVEND STUDY
                  In this study, the age and sex adjusted prevalence of 
MicroAlbuminuria in Diabetic, hypertensive and in non–diabetic non–
hypertensive  subjects  was  16.4,  11.5  and  6.6  %  respectively. 
Advanced  age,  male  sex,  hyperlipidaemia,  smoking,  myocardial 
infarction and stroke  were more frequently seen in  subjects  with 
Urinary 
Albumin 
Excretion       
0-10 mg/L
(n=30,670)
10-20 mg/L
(n=6,749)
20-200 mg/L
(n=2,918)
>200 mg/L
(n=282)
Total
(n=40,619)
Age, Year, Mean 
(S.D)
49.4 (12.7) 47.9(12.9) 53.1 (13.2) 57.2(12.7) 49.5(12.9)
Male, % 43.4 51.5 53.8 59.2 45.6
Morning Urine 
Albumin,Median
4.9 12.7 32.7 351.0 6.1
(25th-75th 
percentile)
(3.2-6.9) (11.1-14.9) (24.6-54.0) (254.0-654.0) (3.8-9.9)
Diabetes, % 2.1 2.9 6.2 17.6 2.6
Hypertension, % 10.3 10.9 18.9 38.1 11.2
Hyperlipidaemia,%4.5 4.4 6.7 17.2 4.7
Positive family 
history of 
Cardiovascular 
Disease, %
32.0 31.7 33.2 40.9 32.1
Smoking, % 40.0 48.8 49.4 48.2 42.2
Myocardial 
infraction, %
2.7 2.8 6.0 11.0 3.0
Stroke, % 0.7 0.8 1.6 4.7 0.8
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increased levels of albuminuria. 
          MICROALBUMINURIA AS PREDICTOR OF 
                                   OUTCOME
MICROALBUMINURIA IN VASCULAR DISORDERSS
The association of MicroAlbuminuria with other atherosclerotic 
risk  factors  such  as  diabetes,  hypertension,  dyslipdaemia  and 
smoking  is  well  known.   MicroAlbuminuria  doubles  the  risk  of 
cardiovascular morbidity and mortality and doubles the risk of total 
mortality in diabetes (8,11,12).
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Persistent MicroAlbuminuria in diabetic patients correlates with 
the  presence  of  HTN,  obesity  and  dyslipidaemia.   Hypertensive 
patients  with  MicroAlbuminuria  more frequently develop LVH and 
renal insufficiency. Several studies have revealed the significance of 
MicroAlbuminuria  as  a  predictor  of  increased  mortality  in 
hypertensive patients and in elderly persons (1,13,14).
MicroAlbuminuria is detected early in the course of acute MI 
and is considered an independent predictor of early mortality in the 
condition.
 It  is  of  interest  to  note  that  MicroAlbuminuria  may  even 
precede  manifest  DM,  HTN,  Coronary Artery Disease(CAD)  and 
stroke.  MicroAlbuminuria may be considered as one of the earliest 
manifestation of insulin resistance syndrome(15).
Epidemiological studies suggest that MicroAlbuminuria can be 
regarded as a predictor of ischemic stroke in diabetic and non – 
diabetic subjects.  The thickness of intima – media complex in the 
carotid arteries, which reflect the progression of ahterosclerosis in 
these vessels correlate well with the presence of MicroAlbuminuria 
(7,9).
PROGMOSTIC  SIGNIFICANCE  OF  MICROALBUMINURIA  IN 
STROKE
MicroAlbuminuria was found to be reliable predictor of higher 
mortality  3  months  after  stroke  in  studies  on  its  prognostic 
significance in acute ischemic stroke (10).
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MICROALBUMINURIA  IN  INFECTION,  INFLAMMATION  AND 
TRAUMA
In a study of acute Pancreatitis MicroAlbuminuria peaked at 36 
hrs. after admission and serious complication developed later only in 
those patients with highest level of MicroAlbuminuria, regardless of 
serum amylase concentration (37).
MicroAlbuminuria helped to distinguish bacterial from aseptic 
meningitis with a specificity of 94% (39).
In elective surgery, MicroAlbuminuria measurement displayed 
large  and  more  persistent  rise  in  patients  who  later  developed 
serious complications(38).
Measurement of MicroAlbuminuria in trauma victims 8 hrs after 
admission  predicted  the  development  of  ARDS  with  positive 
predictive value of 85% and negative predictive value of 95%(36).
MICROALBUMINURIA IN CRITICALLY ILL
Measurement  of  MicroAlbuminuria  may  have  role  in  early 
identification  of  patients  at  increased  risk  of  developing  Multiple 
System Organ Failure (MSOF) possibly leading to death i.e. within 6 
hrs  after  admission  to  I.C.U.   This  is  much  earlier  than  current 
clinical scoring system can be used(33).
PATHOPHYSIOLOGY OF MICROALBUMINURIA
The pathogenetic mechanism implicated in MicroAlbuminuria 
includes intraglomerular hypertension, increased filtration fraction of 
albumin, decreased tubular reabsorption of albumin and increased 
glomerular             hydrostatic pressure.
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ELECTRON MICROSCOPIC STUDIES
Electron  microscopic  structural  studies  in  non–albuminuric, 
micro–albuminuric and proteinuric patients  reveal that glomerular 
basement  membrane  width  and  mesangial  fractional  volume 
increase  and  surface  density  of  peripheral  glomerular  basement 
membrane  decrease  with  increasing  severity  in  the  albumin 
excretion rate but with considerable overlap among groups.  The 
strongest  structural  correlation  with  increased  urine  albumin 
excretion was attributed to mesangial fractional volume (16).
MICROALBUMINURIA AND ATHEROSCLEROSIS
Accumulating  evidence  suggests  a  common  pathogenetic 
mechanism for MicroAlbuminuria and premature atherosclerosis, i.e. 
qualitative alterations of the extracellular matrix including decreased 
density and sulfation of Heparan Sulfate – ProteoGlycan (HS–PG) 
complex.  Decreased density of HS in the glomeruli may lead to loss 
of charge selectivity, albuminuria and mesangial proliferation.  In the 
intima of large vessels,  decreased density and/or sulfation of HS 
may  enhance  several  of  the  processes  involved  in  premature 
ahterosclerosis.  Diabetes affects the composition and structure of 
extracellular matrix in many ways and lead to decreased density and 
sulfation of HS – PG by several mechanisms. Genetic differences in 
the sulfation of  HS and/or  genetic  differences in  the coordinated 
biosynthesis  of  HS  –  PG  might  contribute  to  decreased 
concentration and sulfation HS – PG in susceptible individuals(17).
Endothelium dependent as well  as endothelium independent 
vasodilatation  was  found  to  be  significantly  impaired  in  diabetes 
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especially in those with MicroAlbuminuria.  The demonstration that 
MicroAlbuminuria diminishes promptly with short–term reduction in 
arterial  BP  argues that  reversible  haemodynamic  factors  play an 
important role in the pathogenesis of MA (18).
MECHANISM OF MICROALBUMINURIA IN ACUTE STROKE
The  mechanisms  determining  the  occurrence  of 
MicroAlbuminuria  in  acute  ischemic  stroke  have  been studied  in 
relation to biochemical markers of stress and inflammatory reactions 
as well  as  markers  of  endothelial  damage including haematocrit, 
ESR,  plasma  glucose,  fibrinogen,  leukocytosis,  thrombocytosis, 
vonwillebrand factor activity, IL – 6 and urinary epinephrine and nor 
epinephrine.   Significant  association  has  been  found  with 
vonwillebrand factor activity, urinary epinephrine on day 1 and serum 
IL – 6 in varying studies (19,20,21).
DETECTION OF MICROALBUMINURIA
The test include
A. Immunoturbidimetric method – Depends on the turbidity of solute 
when  albumin  in  the  sample  of  urine  reacts  with  specific 
antibody.  The turbidity is measured with a spectrophotometer 
and absorbance is proportional to the albumin concentration.
B. Immunonephelometric  method –  Albumin  in  the urine sample 
form light scattering antigen – antibody complex when it reacts 
with   specific  antibody  which  can  be  measured  with  laser 
nephelometer.
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C. Radioimmunoassay –  Albumin  in  the urine sample  competes 
with a known amount of radiolabelled albumin for fixed binding 
sites of antibodies.  Free albumin can be separated from bound 
albumin by immuno – adsorption of the albumin bound antibody. 
Albumin concentration in the sample is inversely proportional to 
radioactivity.
D.   ELISA  –  Competitive  ELISA  can  also  be  used  for  testing 
MicroAlbuminuria.
The  tests  mentioned  so  far  measure  the  total  protein  or 
albumin concentration.  In an effort to correct for problems relating to 
variability in urine volume and concentration, many investigators use 
the Protein Creatinine Ratio(PCR) or Albumin Creatinine Ratio(ACR) 
in  Random or  Timed volume collection.  There is  high degree of 
correlation between 24 hrs urine protein concentration and PCR.
SCREEING FOR MICROALBUMINURIA
Considering  the  importance  of  MicroAlbuminuria  in  various 
disease processes, screening for MicroAlbuminuria is acceptable in 
clinical practice.  In fact, annual screening for albuminuria in patients 
with  diabetes  is  recommended  in  the  guidelines  of  American 
Diabetes Association (ADA). Screening may also be contemplated 
in  patients  with  Hypertension,  Hyperlipidaemia  and  those  who 
smoke.   The report  that  MicroAlbuminuria may precede manifest 
Diabetes, Hypertension, Coronary artery disease and Stroke raise 
serious doubt whether we should limit  our screening strategies to 
those with known risk factors or preferably should screen general 
population(5).
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SCREENING STRATEGY 
NEWER SCREEING METHODS
In addition to the measurement of Albumin to Creatinine ratio 
or Albumin concentration in a Random or Timed Urine Samples, an 
array  of  newer  screening  tests  are  being  developed  to  test 
MicroAlbuminuria.   These  include  the  MICRAL  –  II  test  and 
Immunodip test.
Multicentre trials show that MICRAL – test II immunologic test 
strips  permits  an  immediate  and  reliable  semiquantitative 
determination  of  low  albumin  concentration  with  an  almost  user 
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independent colour interpretation (22).  But considering the higher 
cost of MICRAL strips and the better sensitivity and specificity of the 
measurement of Urine Albumin Concentration or Urine Albumin to 
Creatinine ratio, the latter may still be the test of choice for screening 
for MA (23).
THERAPEUTIC IMPLICATIONS OF MICROALBUMINURIA
Angiotensin  Converting  Enzyme  Inhibitors  (ACE-I)  or 
Angiotensin  Receptor  Blockers  (ARB),  are  the  most  effective  in 
lowering  urine  albumin  excretion.   It  has  been  shown  in  many 
patients  with  manifest  renal  disease  that  in  those  with  overt 
proteinuria of more than 300 mg/day, the extent to which proteinuria 
is lowered during treatment predicts the prevention of both chronic 
kidney disease and cardiovascular disease.  It is likely that the same 
holds true for microalbuminurics also (24,25). 
RELEVANCE OF THE STUDY
The measurement of MicroAlbuminuria is a simple quick and 
non invasive technique that  is  showing promise as an early and 
sensitive  indicator  of  disease  severity  in  a  range  of  clinical 
conditions.  If  so,  MicroAlbuminuria  shall  prove  to  be  useful  for 
targeting early and aggressive treatment in those prone for severe 
complication and outcome.
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CEREBROVASCULAR DISEASE
Cerebrovascular diseases include some of the most common 
and devastating disorders  –  ischemic  stroke,  hemorrhagic  stroke 
and cerebrovascular anomalies such as intracranial aneurysm and 
Arterio  Venous  Malformations  (AVM).   The  incidence  of 
cerebrovascular disease increase with age.
ISCHEMIC STROKE
Cerebral ischemia is caused by a reduction in blood flow that 
lasts more than several seconds since neurons lack glycogen. When 
blood flow is quickly restored, brain tissue can recover fully and the 
symptoms  are  only  transient;  this  is  called  Transient  Ischemic 
Attack(TIA). Typically the neurological signs and symptoms of TIA 
last for 5 – 15 minutes but by definition must last less than 24 hrs.
            If the cessation of blood flow lasts for more than a few 
minutes, infarction of brain tissue results. Stroke has occurred if the 
neurologic signs and symptom last for more than 24 hrs.
CAUSES OF ISCHEMIC STROKE
Focal ischemia or infarction is usually caused by thrombosis of 
the cerebral vessels themselves or by emboli from a proximal source 
either an artery or heart.
Cardioembolism is responsible for 20% of all ischemic stroke. 
Emboli  from  heart  most  frequently lodge  in  the  Middle  Cerebral 
Artery  (MCA),  the  Posterior  Cerebral  Artey  (PCA)  or  one  or  its 
branches and infrequently the Anterior Cerebral Artery (ACA).  The 
significant  cause  of  cardioembolism  include  Rheumatic  Heart 
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Disease  (RHD),Non–rheumatic  Atrial  Fibrillation,  Myocardial 
Infarction, prosthetic valves and cardromyopathies.
Thrombus formation in atherosclerotic plaques in extracranial 
arteries can embolise to intracranial arteries produce an  Artery to 
Artery Emboli stroke.  The most common source of embolism is the 
carotid bifurcation.
Intracranial  atheroselerosis  produce  stroke  either  by  an 
embolic mechanism or in situ thrombosis of diseased vessels.
Other  less  common  cause  of  stroke  include  Dissection  of 
internal carotid arteries, vertebral vessels beyond the arch of Willis 
as may occur in Ehler–Danlos type IV, Marfan's syndrome, cystic 
medial necrosis and fibromucular dysplasia; Hypercoagulable states 
like  protein  C  and  S  deficiency;  factor  V  Leiden  mutation, 
polycythaemia  and  sickle  cell  anemia;  Fibromuscular  dysplasia; 
giant cell  arteritis; Wegener's granulomatosis; Moyamoya disease; 
Reversible  posterior  leukencephalopathy;  Binswanger  disease 
(Chronic  progressive  subcortical  encephalopathy);  CADASIL 
(Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarct 
and Leukencephalopathy)(40).
IMAGING STUDIES IN ACUTE ISCHEMIC STROKE
CONVENTIONAL COMPUTED TOMOGRAM(CT)  
The  major  role  of  the  unenhanced  CT  is  to  exclude  the 
haemorrhagic lesion.  Conventional CT may be normal within 6 hrs. 
of symptom onset and early CT hypodensity represents tissue that is 
doomed for irreversible infarction.  
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MULTIDETECTOR CTs
Include CT Angiogram(CTA) and CT Perfusion studies (CTP). 
CTA is a very good tool to evaluate the vascular status of the neck 
and intracranial vessels.
CTP  studies  use  several  parameter  maps  like  the  Time  to 
Peak Map (TTP), the Mean Transit Time (MTT) Map, the Cerebral 
Blood Flow(CBF) Map and the Cerebral Blood Volume(CBV) Map. 
The Timed Maps are very sensitive to haemodynamic abnormality 
while  the  CBF and  CBV  maps  predict  the  outcome of  ischemic 
lesion.  
CONVENTIONAL MAGNETIC RESONANCE (MR) IMAGING
Conventional  MRI though reliably documents the extent and 
location of infarction in all areas of the brain, including the posterior 
fossa and the cortical surface; it is less sensitive to detect acute 
blood.  Besides, it  is quite insensitive to acute ischemic change. 
Magnetic  Resonance  Angiogram(MRA)  visualizes  the 
cerebrovascular  anatomy  non–invasively  without  any  radiation 
hazard.  
DIFFUSION WEIGHTED IMAGING (DWI)
Areas  of  Diffusion  Weighted  Imaging  (DWI)  changes  or 
significant  reduction in  the Apparent  Diffusion Coefficient  (ADC) 
were thought  to  represent  irretrievable  tissue  i.e.  they generally 
represent areas of limited reversibility. DWI studies 
are more sensitive to acute ischemic change. 
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PERFUSION WEIGHTED IMAGING (PWI)
MR  Perfusion  Weighted  Imaging  (PWI)  studies  using 
gadolinium contrast are interpreted by various parameters.  Most 
centers generally use a qualitative analysis of the most sensitive 
time map to evaluate the extent of perfusion abnormality. 
DIFFUSION – PERFUSION MISMATCH
Ischemic  Penumbra  has  been  defined  as  the  mismatch 
between  the  diffusion  –  perfusion  abnormalities.   A  significant 
mismatch  has  been  operationally  defined  as  “at  least  20% 
discrepancy between the smaller DWI lesion and the larger PWI 
lesion in their volume”.
MAGNETIC RESONANCE (MR) SPECTROSCOPY
Proton MR Spectroscopy measure several  brain metabolites 
including N Acetyl Aspartate (NAA) and lactate.  NAA decreases 
steadily to  50% of the base line value six  hours after  symptom 
onset.  Lactate is a product of anaerobic glycolysis that rises once 
the Cerebral Blood Flow (CBF) decreases below 20ml/100gm/min. 
Ischemic  penumbra  is  defined  as  an  area  with  an  elevation  of 
lactate without any significant decrease of NAA. 
POSITRON EMISSION TOMOGRAM (PET)
PET uses Radiotracers like Oxygen15, Carbon11– Flumazenil 
or  Fluoro  Misonidazole  (F18-MISO)  and  it  assess  the  ischemic 
penumbra by mapping out areas of increased Oxygen Extraction 
Fraction  (OEF)  ranging  from the  normal  value  (0.3–0.4)  with  a 
preserved Cerebral Metabolic Rate of    Oxygen (CMRO2). 
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SINGLE  PHOTON  EMISSION  COMPUTED  TOMOGRAM 
(SPECT)
SPECT uses tracers like Technetium Hexa Methyl Propylene 
Amino Oxime (HMPAO) and Technetium Ethyl Cysteinate Dimer 
(ECD) to demonstrate the location, size and extent of the Cerebral 
Blood Flow (CBF) abnormality after the onset of ischemia.
TRANS CRANIAL DOPPLER (27)
Trans Cranial Doppler (TCD) is a technique to define Cerebral 
Blood Flow Velocity (CBFV) within vessels at the skull base non–
invasively.  TCD has almost  100% sensitivity in acute phase of 
stroke.  The specificity of TCD is very high with proximal occlusion 
as in carotid or Vertebral arteries as well  as in Middle Cerebral 
Artery occlusion.  TCD specificity in Anterior Cerebral or Posterior 
Cerebral Artery territory stroke is relatively low.  TCD has a high 
negative predictive value and it may prevent cerebral angiography. 
TREATMENT OF ACUTE ISCHEMIC STROKE:
ANTIPLATELET AGENTS –
Aspirin as a non–specific cox inhibitor has been widely used in low 
doses.  It blocks TXA2 formation.  
Ticlopidine  and  clopidogrel  block  the  Adenosine  Di 
Phosphate(ADP) receptor on platelets preventing the cascade of 
activation of GP II b/III a receptor that leads to fibrinogen binding to 
platelets.  
Dipyramidole  inhibits  the  uptake  of  adenosine  by platelets  and 
vascular  endothelial  cells,  thereby  causing  accumulation  of 
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adenosine, which is an inhibitor of platelet aggregation.
GP IIb/III a receptor antagonist may have potential application for 
the treatment of acute ischemic stroke and as adjunctive therapy to 
carotid angioplasty.(28)
RECANALISATION THERAPIES
Thrombolysis
Intravenous Thrombolysis
The  National  Institute  of  Neurological  Disorders  and  Stroke 
(NINDs) study showed that administration of rtPA within 3 hours of 
onset of symptom of acute ischemic stroke caused 30% reduction of 
mortality in 3 months (34).
Intra arterial thrombolysis trials
The Prolyse in Acute Cerebral Thromboembolism (PROACT) 
trial  on  the  clinical  efficacy  of  direct  intrarterial  infusion  rPro 
UroKinase  found  a  10–12%  absolute  increase  in  positive 
neurological outcome compared with placebo group at 90 days.
ASSESSMENT OF NEUROLOGIC DEFICIT IN STROKE
Various methods exist for assessing level of consciousness in 
acute stroke clinical trials including the National Institute of Health 
(NIH), Scandinavian Stroke Scale (SSS) and European stroke scale. 
The relationship between Glasgow Coma Scale (GCS) and stroke 
outcome has been studied by a Weir et al (32) and was found that 
each  of  the  component  was  strongly  related  to  outcome. 
Multivariate  analysis  of  individual  GCS  component  identified  the 
verbal and eye component as the best predictors of clinical relevant 
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outcomes. Addition of the eye to the verbal component improved 
sensitivity although specificity was decreased.
The  verbal  score  in  GCS  contain  valuable  prognostic 
information and should be recorded even in dysphasic patients.  The 
maximum verbal  score of  5,  corresponding to a mentated verbal 
response accurately predicted 2 weeks survival and good 3 months 
outcome.  
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MATERIALS AND METHODS 
Setting
                This  study was done in  the inpatient  setting of  
Department  of  Internal  Medicine,  Government  General  Hospital, 
Chennai.
Study Design  
                       Single center Cross sectional study  
Period of study 
                   March-December 2005  
Collaborating Departments
The  study  was  done  with  the  help  of  Department  of 
Biochemistry for various biochemical parameters and Department of 
Radiology for  computed Tomography of  the brain  to  confirm the 
presence of acute ischemic stroke.
Selection of study subjects 
The study subjects were selected from a total sample of 182 
patients admitted with acute ischemic stroke presenting within 24 
hours of stroke onset. They were carefully analysed for the exclusion 
criteria after which the sample size shrunk to 48. 
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                     PATIENT’S FLOW CHART
Inclusion Criteria
The patient profile studied included both males and females 
aged from 25-83 years admitted within 24 hours of onset of acute 
ischemic stroke as confirmed by computed Tomography. 
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Exclusion Criteria   
The Exclusion Criteria was fairly rigid, it was:
 1.positive urine analysis including Haematuria, Pyuria,   
    Proteinuria, Glycosuria
 2. Kidney diseases both congenital and acquired
 3. Diabetes Mellitus
 4.Liver disease
 5. Chronic Inflammatory Gastrointestinal disorder
 6. Neoplasm
 7. Any sign of infection
 8. Coronary Artery Disease or Acute Coronary event
 9. Other congenital or endocrine disorder
 10. Inflammatory Rheumatic disease
 11. Dyslipidemia
 12.Those on Non-steroidal Anti-inflammatory drugs or  
      Immunosuppresants 
 13.Fever
 14.Other chronic infective or inflammatory disorders 
 15.History of Hypertension
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Details of study subjects 
Demographic data 
                The study group included patients from all over Tamil 
Nadu and adjacent states in keeping the status of the institution as a 
tertiary care referral centre
Clinical and Laboratory Details
All  patients  on  admission  had  their  history  taken  and 
underwent  a  thorough  clinical  check  up.  The  severity  of  the 
neurological deficit was assessed according to the Glasgow Coma 
Scale.
The patient or the caregiver was interviewed to establish the 
past medical and personal history.
          All patients had their Blood Pressure and Electrocardiogram 
taken.
          Acute ischemic stroke was documented by computed tomogram
           Blood Glucose levels were measured on day 1 and serially on 
days  3,5  and  7.   Haematocrit,  WBC  count,  Blood  Urea,  Serum 
Creatinine and Electrolytes and Lipid profile of the patients were also 
noted.
The Alubmin Excretion Rate was assessed in a 24 hours Urine 
collection performed on day 2. Urine Albumin Excretion was done by 
the  IMMUNOTURBIDIMETRIC  METHOD.  It  was  expressed  as 
mg/day. 
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Definitions 
A daily Urinary Albumin Excretion below 30 mg was considered 
to be within the normal range.
Microalbuminuria was defined as urine albumin excretion rate 
between 30 and 300 mg/day.
Proteinuria was defined as Urine albumin excretion rate of 
more than 300 mg/24 hours.
                  ECG evidence of Left Ventricular Hypertrophy(LVH) was 
assessed by the Sokolow–Lyon criteria taken as a deep S wave in 
V1 or V2 and a tall R wave in V5 or V6 with the sum of the two 
deflexions exceeding 35 mm. 
Glasgow Coma Scale was assessed as follows:- 
  Eye opening               4-Spontaneously 
                                      3-To verbal stimuli
                                      2-To pain  
                                      1-Never 
 Best Verbal response 
                                      5-Oriented and converses 
                                      4-Disoriented and converses 
                                      3-Inappropriate words 
                                      2-Incomprehensible sounds 
                                      1-No response 
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  Best motor response 
                                      6-Obeys 
                                      5-Localises pain 
                                      4-Flexion withdrawal
                                      3-Abnormal flexion (decorticate rigidity) 
                                      2-Extension (decerebrate rigidity) 
                                      1-No response
Study Details
       In the study, we primarily grouped the patient into Group A i.e. 
Patients with Microalbuminuria and  Group B i.e. Patients without 
Microalbuminuria i.e. Normalbuminuric patients.  This was to assess 
the prevalence of Microalbuminuria in Acute Ischemic Stroke.
These two study groups were then compared with reference to 
their  Age,  Gender,  GCS,  ECG  evidence  of  LVH,  Systolic  and 
Diastolic Blood Pressure.
Significant correlation was sought between: 
Urine Albumin Excretion and Age 
Urine Albumin Excretion and Gender
Urine Albumin Excretion and Glasgow Coma Scale
Age and Glasgow Coma Scale. 
                Urine Albumin Excretion and Left Ventricular Hypertrophy.
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Limitation of Study
The prognostic  parameter studied was confined to 
Urine Albumin Excretion and GCS.  Death or Functional outcome of 
the patient after treatment could not be followed up 
                   As the study was conducted in a referral tertiary institute, 
there might be an inadvertent selection bias towards the seriously ill. 
The  reproducibility  of  the  same  in  wider  settings  needs  to  be 
investigated further.
Statiscal Analysis
The  Statistical  Analysis  was done using  a  SPSS  Statistical 
Software Package. 
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                               RESULTS
                  The study group included 48 patients. 
Microalbuminuria was present in  23 of the 48 patients. 
                   The study group was again divided into two basic groups 
that is  
                   Group A – Patients with Microalbuminuria and   
                   Group B – Patients without Microalbuminuria  
 
                  of Left Ventricular Hypertrophy in ECG.  
Intra–group comparisons and correlation studies were done
   The baseline characteristics of the patients with Microalbuminuria 
and patients without Microalbuminuria are 
given below in tables 2 and 3. These two groups were mainly 
compared in terms of their  Age, Gender, GCS, Blood Pressure and 
presence/absence of Left Ventricular Hypertrophy.
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Table No.2 ­ Baseline Characteristics in Patients with 
Microalbuminuria (Group A)
Sl.No. NAME AGE SEX SBP∗ DBP# LVH♣ GCS♦ UAE♠
3 S 62 M 160 100 + 5 118
5 S 54 M 156 90 - 10 86
7 S 58 M 180 110 - 9 48
9 R 54 M 140 80 + 3 144
10 S 60 M 170 114 + 5 124
12 S 56 M 200 100 + 4 92
13 A 70 M 146 92 - 9 88
14 M 50 M 140 80 - 14 76
16 C 43 M 170 124 + 6
17 E 70 M 150 90 - 9 45
18 P 75 M 164 86 - 9 38
20 R 57 M 156 94 - 9 44
21 K 65 M 150 90 - 11 71
23 P 65 M 144 88 - 8 45
25 G 75 M 160 80 - 12 40
27 M 52 M 176 94 + 8 93
31 B 65 F 130 80 - 11 51
33 K 85 F 144 70 - 8 86
35 B 75 F 160 108 + 9 79
40 G 50 F 154 92 - 10 58
43 R 65 F 170 100 - 9 48
44 P 80 F 140 90 - 7 117
45 C 85 F 170 116 - 6 92
∗ Systolic Blood Pressure          # Diastolic Blood Pressure  ♦ Glasgow Coma Scale
♣ Left Ventricular Hypertrophy    ♠ Urine Albumin Excretion
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Table No.3 - Baseline Characteristics in Patients without 
Microalbuminuria(Group B)
Sl.No. NAME AGE SEX SBP∗ DBP# LVH♣ GCS♦ UAE♠
1 A 45 M 150 96 - 11 18
2 C 46 M 164 106 + 11 10
4 M 45 M 140 86 - 12 19
6 K 72 M 138 92 - 11 26
8 K 55 M 154 100 - 10 28
11 M 63 M 146 92 - 10 15
15 E 45 M 156 80 - 12 13
19 R 58 M 170 96 + 13 14
22 C 55 M 160 90 - 8 13
24 D 58 M 148 82 - 10 17
26 A 50 M 136 70 - 8 14
28 C 50 M 140 90 - 11 10
29 S 47 M 150 80 - 12 28
30 V 45 M 148 96 - 13 23
32 S 67 M 150 100 - 10 16
34 V 40 F 130 84 - 13 7
36 C 65 F 154 90 - 14 18
37 V 61 F 160 80 - 14 19
38 R 50 F 164 104 + 13 26
39 V 60 F 170 80 - 13 20
41 V 25 F 150 90 - 11 18
42 R 65 F 166 110 + 14 11
46 A 55 F 150 94 - 13 15
47 M 65 F 140 80 - 14 12
48 K 70 F 130 100 - 13 17
      ∗ Systolic Blood Pressure     # Diastolic Blood Pressure 
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♣ Left Ventricular Hypertrophy    ♦ Glasgow Coma Scale      ♠ Urine Albumin Excretion
       Table No.4 - Baseline Characteristics and outcome in 
Patients with and without MicroAlbuminuria (MA)
Category Patient with MA Patient without MA
No. of Cases 23 25
Age  (Mean) 63.96  + 11.93 54.28  +  10.86
Gender in 
percentage
M 17(73.91%) 15(60%)
F 6(26.08%) 10(40%)
Systolic BP (Mean) 157.83 + 16.01 150.56 + 11.50
Diastolic BP (Mean) 94.26 + 13.27 90.72 + 9.76
ECG with LVH (30%) (16%)
Urine Albumin Excretion 78.17 + 31.02 17.01 + 5.69
Glasgow Coma Scale 8.30±2.62 11.76±1.76
          Patients with Microalbuminuria (Group A) & Patients without 
Microalbuminuria (Group B) were compared with reference to sample 
sizes, Age, Gender, Systolic BP, Diastolic BP, ECG evidence of   left 
ventricular hypertrophy & Glasgow Coma Scale as given in Table 4. 
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           Table No.5 – UAE♣ in Patients Studied
Category of Cases
Number of 
Cases
UAE in mg / day
Mean + SD Median 25th Percentile 75th Percentile
Patient with MA # 23 78.17 + 31.02 79 48 93
Patient without MA # 25 17.01 + 5.69 17 13 19
Whole Study group 48 46.35 + 36.77 28 17 78
♣ Urine albumin Excretion
# Micro albuminuria
P<0.001 (significant at 1 %  level)
             The Mean, Median, 25th & 75th percentile of the Urine    
       Albumin Excretion of the patients in Group A & B was as given   
       in Table 5 
       The  mean  Urine  Albumin  Excretion  in  patients  with 
Microalbuminuria was found to be 78.17 + 37.02. 
The  mean  Urine  Albumin  Excretion  in  patients  without 
Microalbuminuria was found to be 17.01 + 5.69.        
The mean Urine Albumin Excretion in the whole study group 
was found to be 46.35 + 36.77.
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Table No.6 – Glasgow Coma Scale (GCS) in Patients with 
MicroAlbuminuria (MA) and without MicroAlbuminuria (MA)
    GROUP A   GROUP B
WITH MA WITHOUT MA
GCS# GCS
Mean 8.30 + 2.62 11.76 + 1.76
Median 9 12
25th Percentile 6 11
75th Percentile 10 13
P < 0.001 -Significant at 1% level
#Glasgow Coma Scale
Glasgow Coma Scale of patients with and without MicroAlbuminuria 
was compared as given in table 6.
The mean GCS in patients in Group A was 8.30 + 2.62.
The mean GCS in patients in Group B was 11.76 + 1.76.
The mean GCS of patients in Group A was significantly  lower 
than that of patients in Group B.  
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Table No.7 - Age in Patients with MicroAlbuminuria (MA) and 
without MicroAlbuminuria (MA)
   GROUP A       GROUP B
WITH MA WITHOUT MA
AGE AGE
Mean 63.96 + 11.53 54.28 + 10.86
Median 65 55
25th Percentile 54 46
75th Percentile 75 63
P < 0.001 –significant at 1%level
The age of patients in Group A & B were compared as given in 
Table 7
The mean age of patients in Group A was 63.96 + 11.53
The mean age of patients in Group B was 54.28 + 10.86
        The mean age of patients in Group A was significantly 
        higher in Group A than in Group B. 
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Table No.8 - Age in relation to Gender
AGE in years
MEAN MEDIAN 25TH PERCENTILE 75TH PERCENTILE
WITH MA
(Group A)
MALE 60.65 + 8.93 60 54 65
FEMALE 73.33 + 13.66 77.50 65 85
COMBINED 63.96 + 11.53 65 54 75
WITHOUT MA
(Group B)
MALE 53.40 + 8.75 50 45 58
FEMALE 55.60 + 13.87 60.50 50 65
COMBINED 54.2 + 10.86 55 46 63
               The age of the patients in Group A & Group B were         
   compared in relation to gender as given in Table 8
                In Group A, the Mean Age of Male & Female patients were   
    60.65 + 8.93 and 73.33 + 13.66 respectively.
In Group B, the Mean Age of Male & Female patients were
     53.40 + 8.75 and 55.60 + 13.87 respectively.
The Female in Group A were older than Males.
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Table No.9 –Urine Albumin Excretion in Patients older than 60 
years and younger than 60 years in Patients with and without 
MicroAlbuminuria
           GROUP A           GROUP B
WITH MA WITHOUT MA
AGE Group AGE Group
< 60 > 60 < 60 > 60
UAE UAE UAE UAE
MEAN 88 + 32.97 70.62 + 28.39 17.24 + 6.25 16.75 + 4.75
MEDIAN 89 71 17 16.50
25th Percentile 58 45 13 13.50
75th Percentile 115 80 20 18.50
P = .713 in PTS without MA < 60 yrs ; P = 0.696 in Patients with MA < 60
P = .202 in PTS without MA > 60 yrs ; P = .386 in Patients with MA > 60
An intra group comparison was made to find out any correlation of 
Urine Albumin Excretion with age as given in table 9.
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Table No.10 – UAE in mg / day in relation to Gender
Category Gender 
Number of
 Cases
Mean + SD Median
25th Percentile 75th Percentile
Patients with 
MA
Male 17 77.53 + 33.62 76 45 58
Female 6 80.00 + 24.73 82.50 93 92
Patients 
without MA
Male 15 17.60 + 6.05 16 13 23
Female 10 16.30 + 5.33 17.50 12 19
P = 0.871 in Patient with MA
P = 0.087 in Patient without MA
The Urine Albumin Excretion (UAE) of Male & Female Patients was 
calculated separately as given in Table 10.
The Mean Urine Albumin Excretion of Male Patients in Group 
A was 77.53 + 33.62.
The Mean Urine Albumin Excretion of Female Patients in 
Group A was 80.00 + 24.73.
The Mean Urine Albumin Excretion of Male Patients in Group 
B was 17.60 + 6.05.
The Mean Urine Albumin Excretion of Female Patients in 
Group B was 16.30 + 5.33.
From this it can be deduced that Mean Urine Albumin 
Excretion of Females was slightly higher in Group A. 
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Table No.11 - Correlation coefficients of Age, UAE and GCS in 
Patients with MA 
Category UAE GCS
AGE
Л = - .1707
p = .436
Л = .0366
p = .860
UAE
--
--
Л = - .6895
p = .000*
*p < 0.01 − Significant at 1% level
Figure 2: Graph showing the relationship between GCS and UAE
The Correlation studies done with reference to Urine Albumin 
Excretion(UAE), Age and Glasgow Coma Scale(GCS) is given Table 
11 and Figure 2
There  is  significant  Correlation  between  Urine  Albumin 
Excretion and GCS in Group A while no such correlation was found 
in Group B.
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Table No.12 - Correlation Coefficients of Age, UAE & GCS in 
Patients Group B 
Category UAE GCS
AGE
Л = - .0636
p = .763
Л = .1560
p = .457
UAE
- -
- -
Л = - .0103
p = 0.961
But there was no significant correlation between GCS and UAE in 
group B.
Table No.13 - Mean UAE in Relation to 
Presence / Absence of LVH
CATEGORY
WITH MA WITHOUT MA
No. of Cases UAE mg/day No. of Cases UAE mg/day
LVH
Present 7 109.29 + 22.40 4 15.25 + 7.37
Absent 17 64.56 + 23.69 21 17.43 + 5.47
P - 0.000* in Patients with MA                        * - Significant at 1% level
P - .495# in Patients without MA                    # -  Not Significant
We also looked into correlation of Urine Albumin Excretion (UAE) 
with Left Ventricular Hypertrophy (LVH) as given in table 13 
The patients with LVH in Group A had significantly higher Urine 
albumin excretion than patients without LVH.
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DISCUSSION
The  association  of  Microalbuminuria  in  cerebrovascular 
diseases has been confirmed in a few Western studies.  This study 
was  undertaken  to  analyze  Microalbuminuria  in  acute  cerebral 
ischemic events in our context. After analysis of 182 patients with 
reference  to  inclusion  and  exclusion  criteria,  48  patients  were 
selected for the study.
STRENGTH OF THE STUDY
My study was based on sample size of 48 subjects.  Though 
the study size is relatively small,  it  may still  be relevant since the 
exclusion criteria was fairly rigid including all patients with diabetes, 
history of hypertension, history of coronary artery disease or acute 
coronary event, any infective or inflammatory disorder, positive urine 
analysis, fever, history of chronic nonsteroidal anti inflammatory drug 
intake.  The  study  was  confined  to  patients  with  purely  acute 
ischemic stroke.  Therefore the crux of the study is the association of 
Microalbuminuria with acute cerebral infarction where other factors 
that may influence albumin excretion were excluded.
LIMITATION OF STUDY
Since  the  study was  carried  out  in  a  tertiary  care  referral 
institute, the reproducibility of these findings in the same cohort of 
patients in a more general setting is to be investigated   further.  
Being  a  single  centre  cross  sectional 
study,  there  might  be  an  inadvertent  selection  bias  towards  the 
seriously ill and the lack of data regarding the final outcome of death 
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in this study may have its own pitfalls.
PREVALENCE OF MICROALBUMINURIA
In  this  study  Microalbuminuria  was  present  in  23  of  48 
subjects,  which  amounted  to  prevalence  of  47%.   This  was 
conforming to the past studies in acute cerebrovascular accidents. 
Previous studies are given in table 14.
Table  14-  Prevalence  studies  of  microalbuminuria  in  acute 
ischemic stroke 
Study Sample size Prevalence  in 
cases
Prevalence  in 
controls
year Journal
Turaj et al 52 46%  13% 2001 Med Sci Monit
Beamer et al 97 30% 10% 1999 Arch Neur
In both these studies, controls had similar risk factor profile to those 
with acute ischemic stroke studied including coronary artery disease 
and  hypertension.  These  studies  noted  higher  prevalence  of 
microalbuminuria in acute stroke compared to risk factor adjusted 
controls. 
          Prevalence rate of Microalbuminuria in stroke is similar to that 
reported in other conditions.  In diabetes the reported prevalence of 
Microalbuminuria  was  3  to  40%  (5,6,7).   Hypertensives  had  a 
reported prevalence of 3 to 37%(8,31).  This study had a relatively 
high prevalence of Microalbuminuria in acute phase of stroke.
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PROGNOSTIC SIGNIFICANCE OF MICROALBUMINURIA
The prognostic significance of Microalbuminuria was studied in 
relation  to  Glasgow Coma Scale  (GCS).   Past  studies  (10)  had 
shown significant correlation of Microalbuminuria with Scandinavian 
Stroke  Scale  (SSS)  in  acute  Ischemic  Stroke  confirming  its 
prognostic  significance.  We  used  a  different  scale  that  is  the 
Glasgow Coma Scale to assess the severity of neurological deficit.
Glasgow  Coma  Scale  and  stroke  outcome  had  significant 
correlation in past studies (32).  
Mean Glasgow Coma Scale of patients with Microalbuminuria 
was significantly lower than that of patients without Microalbuminuria 
(8.30±2.62 vs 11.76±1.76).  There was also a significant negative 
correlation of Glasgow Coma Scale with urine albumin excretion in 
our study (SeeTables 6 &11).  The lower the Glasgow Coma Scale 
the  more  the  urine  albumin  excretion  and  vice  versa.   Hence 
Microalbuminuria may be an important prognostic marker in stroke.
Therefore  measurement  of  microalbuminuria  may  help  to 
assess who is at increased risk and to triage those who may need a 
more aggressive management protocol.
AGE, GENDER AND URINARY ALBUMIN EXCRETION
The  patients  with  Microalbuminuria  were  significantly  older 
than the patients without Microalbuminuria in our study.  This was 
also conforming to the past studies (10). 
                 Past studies have shown significant association between 
albuminuria and advanced age (9,10,31).
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But no significant graded correlation was found between age 
and  urinary  albumin  excretion  in  both  Microalbuminurics  and 
normalbuminurics  in  our  study.   An  intragroup analysis  was also 
done i.e. by grouping the patients to less than 60 years and more 
than  60  years.   Still  urine  albumin  excretion  and  age  defied  a 
significant graded correlation.
We  infer  that  urine albumin  excretion might  be much more 
dependent  on  the  severity  of  the  stroke  process  than  age  as 
evidenced by its significant correlation with Glasgow Coma Scale in 
acute stroke victims in microalbuminuria.  
Female patients were older in our study.  The mean age of 
female patient with microalbuminuria was 73.33 while that of male 
patients was 60.65.
The mean urine albumin excretion was slightly more in female 
subjects, which may be probably due to their advanced age. 
The strong correlation of urine albumin excretion with Glasgow 
Coma Scale than with Age/Gender may be in part due to an acute 
phase inflammatory response (10).
Microalbuminuria  as  a  marker  of  acute  phase  inflammatory 
response  was  documented  earlier  and  it  may  also  foretell  the 
severity of acute phase response (33,35,36,37,39, 42).
AGE, GENDER AND GLASGOW COMA SCALE
There was no significant correlation of Glasgow Coma Scale in 
relation with the gender.  Also there was no significant correlation 
between age and Glasgow Coma Scale in this study.  Early studies 
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had mentioned a more severe correlation between the advancing 
age  and  a  worse  neurological  deficit  (10).   This  could  not  be 
identified in our study.
BLOOD PRESSURE AND MCIROALBIMINURIA IN STROKE
Blood Pressure is a confounding factor in stroke.  In our study, 
patients  with  past  history of  hypertension  came  under  exclusion 
criteria.   But  an  elevated  blood  pressure  is  a  frequent 
accompaniment in stroke.   There was no significant difference in 
blood pressure in  microalbuminirics  and normalbuminurics  in  our 
study.  There was also no correlation between blood pressure and 
urine albumin excretion in patient with or without microalbuminuria.  
                  Studies have reported higher graded prevalence of 
microalbuminuria  in  hypertensives  (24,  31).  The  plausible 
explanation is that there is a certain degree of acute dysautonomia 
in acute stroke events that may not reflect the actual blood pressure 
of the patient.
MICROALBUMINURIA  WITH  ELECTROCARDIOGRAPHIC  
EVIDENCE OF LEFT VERTRICULAR HYPERTROPHY
Microalbuminurics  with  ECG  evidence  of  LVH  had  significantly 
higher rate of albuminuria in our study.  No such correlation could be 
found in normalbuminurics.
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7 out of 23 patients with Microalbuminuria had ECG evidence 
of  LVH.   These  patients  might  have  had  systemic  hypertension 
earlier which might have gone unrecognized and  the higher albumin 
excretion in those with evidence of LVH may have occurred in the 
setting.
Hypertensives  with  Microalbuminuria  were  reported  to  have 
earlier onset of LVH and renal insufficiency (11,13,14).
Smoking and urine albumin excretion 
         No significant comparative studies could be made between 
smoking and albuminuria since the number of  non–smokers among 
males studied was miniscule. Females who were all non–smokers 
had a  higher  mean albumin  excretion,  which  might  be due to  a 
higher mean age of females in our study.
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CONCLUSION
1.   Microalbuminuria  was  present  in  47% acute  ischemic  stroke 
patients studied.
2.  Urine albumin excretion had the strongest correlation with the 
Glasgow  Coma  Scale  of  the  patient  in  Acute  Ischemic  Stroke. 
Those with a lower Glasgow Coma Scale had a higher rate of urine 
albumin excretion and vice versa.
 3.   Acute  ischemic  stroke  patient  with  Microalbuminuria  were 
significantly  older  than  Normalbuminurics  but  there  was  no 
significant graded correlation of Age with urine albumin excretion in 
inter-group and intra–group studies.
4.  There was no significant difference in Blood Pressure in 
     Microalbuminurics and Normalbuminurics.
5.  There was no significant correlation of Blood Pressure with Urine 
Albumin Excretion in acute ischemic stroke. 
6.   Those  with  Electrocardiogram  evidence  of  Left  Ventricular 
Hypertrophy had significantly higher rate of urine albumin excretion.
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SUMMARY
                  Microalbuminuria was long known to be a marker of early 
nephropathy.  Its  importance in  other  disease processes revealed 
itself in further studies. Its association with cerebrovascular diseases 
has been in focus in the last decade or so. This study may still be 
relevant since studies have been far and few between regarding this 
aspect in this part of the country. 
                   The aim of the study was to assess the prevalence of 
microalbuminuria  in  acute  ischemic  stroke  and  to  evaluate  its 
prognostic  significance.  This  study  found  a  47%  prevalence  of 
microalbuminuria in acute ischemic stroke after other factors which 
may confound it  were excluded as far  as possible.  There was a 
significant association and correlation of microalbuminuria with the 
severity  of  the  neurologic  deficit  so  that  it  may be  useful  as  a 
prognostic marker. Microalbuminurics were significantly older than 
normalbuminurics but the strongest correlation was with the severity 
of neurologic deficit. 
                   Further studies are needed regarding this and other 
aspects of microalbuminuria with its emerging role as predictor of 
vascular incidents of heart, brain, kidney as well as in any disease 
process where blood vessels have a significant role. 
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PROFORMA
Name: 
Age: 
Gender: 
Address: 
IP No: 
Presenting illness: 
Past History: 
General Examination: 
Vitals:
System Examination: 
                                CNS:  GCS: 
                                           Higher mental functions: 
                                            Cranial nerves:  
                                            Motor system:  
                                            Sensory system: 
                                            Autonomic nervous system: 
                                             Meningeal signs: 
                                             Skull and Spine:
                                CVS: 
                                   RS: 
                       Abdomen: 
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Investigations: 
      Hematocrit
      TC, DC, ESR 
       Blood urea, sugar, serum creatinine, serum electrolytes, Lipid 
profile 
       ECG 
       Chest X-ray 
       CT Brain 
        24 HRS Urine Albumin Excretion  
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